Icure Pharmaceutical Incorporation

KOSDAQ:A175250 Stock Report

Market Cap: ₩75.1b

Icure Pharmaceutical Incorporation Past Earnings Performance

Past criteria checks 0/6

Icure Pharmaceutical Incorporation's earnings have been declining at an average annual rate of -27.9%, while the Personal Products industry saw earnings growing at 13.8% annually. Revenues have been declining at an average rate of 3.2% per year.

Key information

-27.9%

Earnings growth rate

-17.9%

EPS growth rate

Personal Products Industry Growth3.8%
Revenue growth rate-3.2%
Return on equity-46.1%
Net Margin-39.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Sep 04
Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

Aug 28
Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Jul 21
What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

May 31
Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

May 27
Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

Mar 07
Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

Dec 25
We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

Revenue & Expenses Breakdown

How Icure Pharmaceutical Incorporation makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A175250 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2459,844-23,88822,4993,270
31 Mar 2457,108-28,93921,8863,444
31 Dec 2356,806-31,42021,1843,685
30 Sep 2359,572-34,67815,1753,850
30 Jun 2361,356-38,13515,4123,884
31 Mar 2361,369-42,04014,9544,553
31 Dec 2259,367-41,76613,5544,242
30 Sep 2259,239-38,06713,8213,707
30 Jun 2256,894-41,96315,2003,193
31 Mar 2260,940-40,69017,0892,261
31 Dec 2164,283-38,16720,0042,419
30 Sep 2170,224-29,80725,2262,656
30 Jun 2176,826-20,63828,0002,807
31 Mar 2183,550-15,08327,6223,099
31 Dec 2090,144-12,61427,7903,046
30 Sep 2087,504-19,68425,2912,258
30 Jun 2086,905-15,14324,0222,068
31 Mar 2077,452-9,15324,1322,099
31 Dec 1960,922-8,75121,1561,685
30 Sep 1949,8224,97818,2702,889
30 Jun 1937,867-1,84817,3132,793
31 Mar 1931,479-11,41117,2532,119
31 Dec 1833,320-7,88517,5392,090
30 Sep 1836,227-6,64716,4641,156
30 Jun 1840,747-3,91616,156859
31 Mar 1840,2302,70413,378640
31 Dec 1739,79653812,263599
30 Sep 1737,952-81311,417620
30 Jun 1732,964-1,2318,000691
31 Mar 1730,189-2,8897,544879
31 Dec 1627,279-3,2436,932871
30 Sep 1623,914-3,3675,895898
30 Jun 1619,517-3,8115,241849
31 Mar 1617,967-3,3014,614807
31 Dec 1518,673-2,8783,875670
31 Dec 1414,9309581,009218

Quality Earnings: A175250 is currently unprofitable.

Growing Profit Margin: A175250 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A175250 is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.

Accelerating Growth: Unable to compare A175250's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A175250 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (76.3%).


Return on Equity

High ROE: A175250 has a negative Return on Equity (-46.06%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies